Ron Schutt Email & Phone Number

Retired from President/CEO position after negotiating and signing an exclusive partnership agreement with DOC Brands to manage the ongoing growth of the OrVance® brands and products. The Board Chair position oversees the ongoing governance and strategic direction of OrVance LLC, serves as an Advisory Board Member to the OrVance-DOC Brands Venture, and is.

Became the Founding CEO of OrVance in 2014 to raise capital and to develop and launch several proprietary products including OrthoDots® CLEAR, OrVance® Aligner Pontics and OrVance® Temporary Tooth Repair (TTR™). In April 2022, negotiated and signed an exclusive licensing agreement for DOC Brands to manage all Operations, Sales, Marketing, and Distribution..

Provided support in the planning and execution of major new business ventures: interim leadership, business & go-to-market planning, optimizing marketing mix, raising capital, and business development/partnerships.

Served in an interim role at Hope Network to develop a strategic plan for Marketing & Fundraising and to implement a leadership/team structure around these new plans. Areas of responsibility included Marketing, Fund Development, and Government Affairs. Developed a new strategic plan and established Marketing and Development leadership by hiring top caliber.

Allegan, MI

Led all aspects of marketing for Perrigo's U.S. OTC pharmaceutical business, which provided revenues of over $1.3 billion. Championed the entry into new business segments such as Diabetes, ORx (OTC drugs sold by prescription), and managed the launch of Omeprazole (equivalent to Prilosec OTC®) which delivered record-breaking revenues of over $200 million..

Responsible for Business Development, Marketing, Portfolio Management, and Business Planning for the newly entered Rx/Generic drug business. Negotiated product agreements and supported the integration efforts for the acquired Agis business - an $800+ million acquisition of a generic drug & API business based in Israel.

Responsible for growing Perrigo's Rx to OTC drug portfolio by negotiating exclusive product agreements, portfolio management, project management, and managing the R&D budget. Primary Rx to OTC drug classes included H2s, PPIs, Nicotine Replacement Therapy, NSAIDs, and Non-Sedating Antihistamines. Also assumed leadership role in defining Perrigo's entry.

Responsible for marketing and product development functions in the International Division. Led business planning, product development, market research, and sales support. Managed new product development for Japan and led research projects to study the feasibility of entering new markets.

Accepted first foreign assignment within Perrigo to lead a joint feasibility study with Mitsui, for the Store Brand opportunity in Japan. Directed market research and developed business plans which led to establish Perrigo's presence in Japan. Supported new product launches to first customers in Japan and completed an abbreviated feasibility study of the.

Joined Perrigo to lead market research, portfolio management, and business planning in the early stages of its R&D investments in Rx to OTC switches. Developed proprietary database of Rx to OTC switch opportunities, developed financial models, and project management for new product development.

Responsible for the market research and information management aspects of direct marketing during the start-up phase of DTC marketing at Foremost.

Progressed from junior level analyst to lead systems design, project management, and ROI analysis for major IT initiatives.

M.B.A., Business Administration/Marketing

B.S., Business/Computer Information Systems